SMART 101
Alternative Names: ProTcells™ (CD7+/CD34-; CD5- cells); ProTcell™; SMART-101Latest Information Update: 21 Dec 2023
At a glance
- Originator Smart Immune
- Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Precursor B-cell lymphoblastic leukaemia-lymphoma; Severe combined immunodeficiency
- Clinical Phase Unknown Unspecified
Most Recent Events
- 16 Oct 2023 Phase-I/II clinical trials in Myelodysplastic syndromes in France (Parenteral) (NCT05768035)
- 28 Jun 2023 Preclinical trials in Acute myeloid leukaemia in France (Parenteral) (Smart Immune pipeline, June 2023)
- 28 Jun 2023 Preclinical trials in Myelodysplastic syndromes in France (Parenteral) (Smart Immune pipeline, June 2023)